Gilead Sciences, Inc. $GILD Stock Holdings Boosted by TD Asset Management Inc

TD Asset Management Inc raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% in the third quarter, HoldingsChannel reports. The firm owned 3,424,991 shares of the biopharmaceutical company’s stock after acquiring an additional 4,315 shares during the period. TD Asset Management Inc’s holdings in Gilead Sciences were worth $380,174,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GoalVest Advisory LLC grew its position in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences in the 3rd quarter worth about $26,000. Putney Financial Group LLC raised its position in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences during the second quarter worth $30,000. Finally, MTM Investment Management LLC raised its holdings in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director owned 8,920 shares in the company, valued at approximately $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 317,085 shares of company stock worth $44,734,886. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on GILD shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Mizuho raised their price target on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Rothschild & Co Redburn increased their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Leerink Partners boosted their price target on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Finally, Truist Financial raised their price objective on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $155.44.

Gilead Sciences Price Performance

Shares of GILD stock opened at $147.64 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The firm has a fifty day moving average of $134.64 and a 200-day moving average of $124.28. The firm has a market capitalization of $183.17 billion, a price-to-earnings ratio of 21.81, a price-to-earnings-growth ratio of 1.99 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.